A Controlled-Study on the Effect of a Combination of Fenofibrate and Metformin on Weight Loss and Weight Loss-Maintenance, in Obese Patients.

This study has been completed.

First Received: July 6, 2006 Last Updated: August 31, 2007 History of Changes

Sponsored by:	Solvay Pharmaceuticals
Information provided by:	Solvay Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT00349635

Purpose

To investigate the effect on body weight of a combination fenofibrate and metformin on top of a moderate balanced calorie-deficit diet.

Condition	Intervention	Phase
Obesity	Drug: Metformin and Metformin + Fenofibrate	Phase II

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title:	A Double-Blind, 3-Arm Study on Weight Loss With a Combination of Micronised Fenofibrate 267 mg and Metformin 1,700 mg Per Day Compared to Metformin 1,700 mg and to Placebo, at 6 Months, in Obese Patients, Followed by: A Double-Blind, 2-Arm Investigation of Weight-Loss Maintenance With the Same Combination of Micronised Fenofibrate 267 mg and Metformin 1,700 mg Compared to Placebo, at 6 Months, in the Responders.

Resource links provided by NLM:

MedlinePlus related topics: Diets Obesity Weight Control

Drug Information available for: Procetofen Metformin Metformin hydrochloride

U.S. FDA Resources

Further study details as provided by Solvay Pharmaceuticals:

Primary Outcome Measures:

Weight

Secondary Outcome Measures:

Waist and hip circumference

Estimated Enrollment:	148
Study Start Date:	October 2004

Eligibility

Ages Eligible for Study:	30 Years to 50 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Both genders, BMI ≥ 30 kg/m² and <40 kg/m².

Exclusion Criteria:

Known abnormal thyroid hormone levels, or high thyroid stimulating hormone (TSH) level.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00349635

Locations

Finland
Site 1
Helsinki, Finland
Site 2
Oulu, Finland
Site 3
Kuopio, Finland

Sponsors and Collaborators

Solvay Pharmaceuticals

Investigators

Study Director:

Global Clinical Director Solvay

Solvay Pharmaceuticals

More Information

No publications provided

Study ID Numbers:	C LF23-0121 04 01, 2004-001731-28
Study First Received:	July 6, 2006
Last Updated:	August 31, 2007
ClinicalTrials.gov Identifier:	NCT00349635 History of Changes
Health Authority:	Finland: National Agency for Medicines

Keywords provided by Solvay Pharmaceuticals:

Weight loss and diet.

Study placed in the following topic categories:

Antimetabolites
Obesity
Antilipemic Agents
Metformin
Overweight
Procetofen
Body Weight

Signs and Symptoms
Hypoglycemic Agents
Weight Loss
Body Weight Changes
Nutrition Disorders
Overnutrition

Additional relevant MeSH terms:

Antimetabolites
Obesity
Molecular Mechanisms of Pharmacological Action
Antilipemic Agents
Metformin
Physiological Effects of Drugs
Overweight
Procetofen
Pharmacologic Actions

Body Weight
Signs and Symptoms
Hypoglycemic Agents
Therapeutic Uses
Weight Loss
Body Weight Changes
Nutrition Disorders
Overnutrition

ClinicalTrials.gov processed this record on September 11, 2009